Pyxis Oncology, Inc.
PYXSAs of the close on Sep 25, 2026
Price
$2.86
Market cap
—
The cover-page share count does not match the latest report's share count
P/E (diluted TTM)
—
Not meaningful: the last four quarters were a loss
EPS (TTM)
−$1.40
Four quarters to Jun 30, 2026
Dividend yield
—
Dividend records do not yet cover the latest payments
Figures shown here come from public SEC filings. Dates beside each section show the available history.
How Pyxis Oncology, Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Source: Pyxis Oncology, Inc. — 10-K filed Mar 23, 2026
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 6 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Mar 25, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| OSAIC HOLDINGS, INC. | 2026-03-31 | 13,721 | Not shown | SEC filing |
| Qube Research & Technologies Ltd | 2026-03-31 | 11,286 | Not shown | SEC filing |
| BARCLAYS PLC | 2026-03-31 | 49,825 | Not shown | SEC filing |
| STATE STREET CORP | 2026-03-31 | 248,837 | Not shown | SEC filing |
| Squarepoint Ops LLC | 2026-03-31 | 17,537 | Not shown | SEC filing |
| DIMENSIONAL FUND ADVISORS LP | 2026-03-31 | 25,912 | Not shown | SEC filing |
| CWM, LLC | 2026-03-31 | 34 | Not shown | SEC filing |
| Longaeva Partners L.P. | 2026-03-31 | 503,214 | Not shown | SEC filing |
| HAGER INVESTMENT MANAGEMENT SERVICES, LLC | 2026-03-31 | 5,000 | Not shown | SEC filing |
| FMR LLC | 2026-03-31 | 11,912 | Not shown | SEC filing |
| J. Derek Lewis & Associates Inc. | 2026-03-31 | 43,000 | Not shown | SEC filing |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 2026-03-31 | 81,260 | Not shown | SEC filing |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 2026-03-31 | 460,997 | Not shown | SEC filing |
| Caitong International Asset Management Co., Ltd | 2026-03-31 | 4 | Not shown | SEC filing |
| Pfizer Inc | 2026-03-31 | 7,032,770 | Not shown | SEC filing |
| FEDERATED HERMES, INC. | 2026-03-31 | 3,181 | Not shown | SEC filing |
| Cornerstone Financial Management LLC | 2026-03-31 | 172 | Not shown | SEC filing |
| GF FUND MANAGEMENT CO. LTD. | 2026-03-31 | 1,316 | Not shown | SEC filing |
| Balyasny Asset Management L.P. | 2026-03-31 | 743 | Not shown | SEC filing |
| NewEdge Wealth, LLC | 2026-03-31 | 116,006 | Not shown | SEC filing |
- Each value is checked against Pyxis Oncology, Inc.'s share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 20 rows: no share price from within three months of their report dates is on file, so they could not be checked.
Filer report history
Two reports per filer, as filed. No change is calculated, because the data on file cannot confirm that both reports describe the same security.
- CITIGROUP INC: 2,902 shares reported 2025-12-31; 1,740 shares reported 2026-03-31.
- SIMPLEX TRADING, LLC: 9,790 shares reported 2025-12-31; 253 shares reported 2026-03-31.
- PACES FERRY WEALTH ADVISORS, LLC: 11,440 shares reported 2025-12-31; 11,440 shares reported 2026-03-31.
- Maia Wealth LLC: 21,959 shares reported 2025-12-31; 21,277 shares reported 2026-03-31.
- BNP PARIBAS FINANCIAL MARKETS: 24,279 shares reported 2025-12-31; 1,654 shares reported 2026-03-31.
- Mirae Asset Global Investments Co., Ltd.: 3,026 shares reported 2025-12-31; 3,248 shares reported 2026-03-31.
- GOLDMAN SACHS GROUP INC: 86,145 shares reported 2025-12-31; 46,920 shares reported 2026-03-31.
- MORGAN STANLEY: 89,222 shares reported 2025-12-31; 69,688 shares reported 2026-03-31.
- Winthrop Capital Management, LLC: 6,000 shares reported 2025-12-31; 6,000 shares reported 2026-03-31.
- Arax Advisory Partners: 14 shares reported 2025-12-31; 1 share reported 2026-03-31.
- China Universal Asset Management Co., Ltd.: 10,146 shares reported 2025-12-31; 11,049 shares reported 2026-03-31.
- NORTHERN TRUST CORP: 101,948 shares reported 2025-12-31; 101,948 shares reported 2026-03-31.
Showing the 12 most recent filer reports.
48 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Pyxis Oncology, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2022-04-21 · Chin Mark: Larger than all 8 other insider sales of Common Stock on file. SEC filing
- 2021-10-13 · Chin Mark: Larger than 11 of the 12 other insider purchases of Common Stock on file. SEC filing
- 2021-10-13 · Chen Bihua: Larger than all 12 other insider purchases of Common Stock on file. SEC filing
Independent insiders buying near the same time
- 2023-09-22–2023-09-28: 7 event(s) across 2 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing , filing , filing , filing , filing )
- 2021-10-13–2021-10-13: 2 event(s) across 2 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing )
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2025-04-21 | HUMPHREY RACHEL · Director | Common Stock | S — Open market or private sale | −13,896 | 1.03 | SEC filing |
| 2025-04-17 | HUMPHREY RACHEL · Director | Common Stock | S — Open market or private sale | −200 | 0.97 | SEC filing |
| 2025-04-14 | HUMPHREY RACHEL · Director | Common Stock | S — Open market or private sale | −1,400 | 0.97 | SEC filing |
| 2024-11-26 | Connealy Pamela Ann · CFO & COO | Common Stock | P — Open market or private purchase | +5,450 | 2.00 | SEC filing |
| 2024-11-26 | Connealy Pamela Ann · CFO & COO | Common Stock | P — Open market or private purchase | +83,400 | 1.96 | SEC filing |
| 2023-09-28 | Connealy Pamela Ann · CFO and COO | Common Stock | P — Open market or private purchase | +8,000 | 1.87 | SEC filing |
| 2023-09-27 | Connealy Pamela Ann · CFO and COO | Common Stock | P — Open market or private purchase | +6,426 | 1.85 | SEC filing |
| 2023-09-27 | Wadhane Jitendra · Chief Accounting Officer | Common Stock | P — Open market or private purchase | +2,500 | 1.87 | SEC filing |
Showing 8 of 19 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-03-24 | Lewis-Hall Freda C · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +45,867 | SEC filing |
| 2026-03-24 | Wadhane Jitendra · Prin Fin & Acct Officer | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +262,635 | SEC filing |
| 2026-03-24 | Wadhane Jitendra · Prin Fin & Acct Officer | Common Stock | A — Grant, award, or other acquisition | +109,461 | SEC filing |
| 2026-03-24 | Palani Santhosh · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +45,867 | SEC filing |
| 2026-03-24 | Metzger Michael A · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +45,867 | SEC filing |
| 2026-03-24 | FLAVIN JOHN L · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +45,867 | SEC filing |
| 2026-03-24 | Cline Darren S · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +45,867 | SEC filing |
| 2026-03-24 | HUMPHREY RACHEL · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +45,867 | SEC filing |
Showing 8 of 21 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2023-03-24 | Sullivan Lara · President and CEO | Stock Option (Right to buy) | D — Disposition to the issuer | −990,461 | SEC filing |
| 2023-03-24 | Sullivan Lara · President and CEO | Stock Option (Right to buy) | D — Disposition to the issuer | −61,825 | SEC filing |
| 2023-03-24 | Wadhane Jitendra · Chief Accounting Officer | Stock Option (Right to buy) | D — Disposition to the issuer | −157,257 | SEC filing |
| 2023-03-24 | Feingold Jay · Chief Medical Officer | Stock Option (Right to buy) | D — Disposition to the issuer | −17,517 | SEC filing |
| 2023-03-24 | Feingold Jay · Chief Medical Officer | Stock Option (Right to buy) | D — Disposition to the issuer | −157,257 | SEC filing |
| 2023-03-24 | Yanchik Connealy Pamela · CFO and COO | Stock Option (Right to buy) | D — Disposition to the issuer | −10,304 | SEC filing |
| 2023-03-24 | Yanchik Connealy Pamela · CFO and COO | Stock Option (Right to buy) | D — Disposition to the issuer | −322,265 | SEC filing |
Showing 7 of 7 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.